Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy. It is also developing various product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone857-259-3860
Debt
Current Ratio18.43
Quick Ratio18.43
Price-To-Earnings
Sales & Book Value
Annual Sales$370,000.00
Price / Sales1,109.88
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees50
OptionableNot Optionable
Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions
What is Scholar Rock's stock symbol?
Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."
What price target have analysts set for SRRK?
4 equities research analysts have issued 1 year price objectives for Scholar Rock's shares. Their forecasts range from $25.00 to $31.00. On average, they expect Scholar Rock's share price to reach $27.3333 in the next twelve months. This suggests a possible upside of 68.0% from the stock's current price. View Analyst Price Targets for Scholar Rock.
What is the consensus analysts' recommendation for Scholar Rock?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scholar Rock.
Has Scholar Rock been receiving favorable news coverage?
Headlines about SRRK stock have been trending positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Scholar Rock earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the next few days.
Who are some of Scholar Rock's key competitors?
Some companies that are related to Scholar Rock include Spark Therapeutics (ONCE), Regenxbio (RGNX), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Orchard Therapeutics (ORTX), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Solid Biosciences (SLDB), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Coherus Biosciences (CHRS) and Novavax (NVAX).
Who are Scholar Rock's key executives?
Scholar Rock's management team includes the folowing people:
- Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 53)
- Mr. Elan Z. Ezickson, COO & Head of Corp. Devel. (Age 54)
- Mr. Yung H. Chyung, Chief Medical Officer (Age 42)
- Ms. Rhonda M. Chicko, Chief Financial Officer (Age 52)
- Mr. Alan J. Buckler, Chief Scientific Officer (Age 58)
When did Scholar Rock IPO?
(SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When did the company's lock-up period expire?
Scholar Rock's lock-up period expired on Tuesday, November 20th. Scholar Rock had issued 5,360,000 shares in its initial public offering on May 24th. The total size of the offering was $75,040,000 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.
How do I buy shares of Scholar Rock?
Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scholar Rock's stock price today?
One share of SRRK stock can currently be purchased for approximately $16.27.
How big of a company is Scholar Rock?
Scholar Rock has a market capitalization of $413.13 million and generates $370,000.00 in revenue each year. Scholar Rock employs 50 workers across the globe.
What is Scholar Rock's official website?
How can I contact Scholar Rock?
Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]
MarketBeat Community Rating for Scholar Rock (NASDAQ SRRK)
MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote "Outperform" if you believe SRRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
